BioSpace News Archive

Elpiscience Biopharmaceuticals, Inc. today announced partner Compass Therapeutics reported positive interim ES104 (also known as CTX-009) Phase 2 data in combination with paclitaxel in patients with biliary tract cancers (BTC).

Jaguar Health, Inc. announced that company management will host an investor webcast on Tuesday, March 10, 2022, at 8:30 a.m. Eastern Time to review first-quarter 2022 financials and provide corporate updates.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) to evaluate Virpax’s Probudur™.

Arcturus Therapeutics Holdings Inc. provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose booster.

The success of monoclonal antibodies in managing wide range of challenging diseases has prompted the further research and development activities in this sector.

Neuromagen Pharma Ltd., developer of a new class of drugs to treat degenerative and senescence-associated diseases, has received FDA Orphan Drug Designation for AGS-499 its lead drug candidate, which has shown significant effectiveness in delaying the onset and progression of ALS (Amyotrophic Lateral Sclerosis).

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn’s management team is scheduled to present at the following upcoming May 2022 conferences.

Aeglea BioTherapeutics, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of registered securities of the Company in a registered direct offering for gross proceeds to Aeglea of approximately $45 million, prior to deducting placement agent fees and estimated offering expenses.

Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is pleased to announce a new study in partnership with Dr. Linda Carlson, Enbridge Research Chair in Psychosocial Oncology at the University of Calgary Cumming School of Medicine.

ViewRay, Inc. announced financial results for the first quarter ended March 31, 2022.